What is he best known for?
The fields of study he is best known for:
- Internal medicine
- Disease
- Cancer
His primary areas of study are Internal medicine, Crohn's disease, Gastroenterology, Inflammatory bowel disease and Surgery.
Jean-Frederic Colombel studied Internal medicine and Placebo that intersect with Clinical endpoint.
His Crohn's disease research incorporates elements of Severity of illness, Clinical trial, Intestinal mucosa and Microbiology.
His research investigates the connection with Gastroenterology and areas like Adverse effect which intersect with concerns in Golimumab.
As a member of one scientific family, Jean-Frederic Colombel mostly works in the field of Inflammatory bowel disease, focusing on Immunology and, on occasion, Irritable bowel syndrome, Anti–Saccharomyces cerevisiae antibody and Genotype.
His Surgery study also includes
- Vedolizumab which is related to area like Induction chemotherapy,
- Natalizumab most often made with reference to Certolizumab pegol.
His most cited work include:
- Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn's disease (4710 citations)
- Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial (3357 citations)
- Infliximab for Induction and Maintenance Therapy for Ulcerative Colitis (2790 citations)
What are the main themes of his work throughout his whole career to date?
His primary scientific interests are in Internal medicine, Crohn's disease, Gastroenterology, Inflammatory bowel disease and Ulcerative colitis.
His Surgery research extends to Internal medicine, which is thematically connected.
His Crohn's disease study combines topics in areas such as Adverse effect, Clinical trial, Randomized controlled trial and Maintenance therapy.
He has researched Gastroenterology in several fields, including Pathology, Placebo, Azathioprine and C-reactive protein.
His study in Inflammatory bowel disease is interdisciplinary in nature, drawing from both Incidence, Epidemiology, Immunology and Intensive care medicine.
His Ulcerative colitis study frequently draws connections between adjacent fields such as Colitis.
He most often published in these fields:
- Internal medicine (58.71%)
- Crohn's disease (38.14%)
- Gastroenterology (36.34%)
What were the highlights of his more recent work (between 2017-2021)?
- Internal medicine (58.71%)
- Inflammatory bowel disease (30.04%)
- Crohn's disease (38.14%)
In recent papers he was focusing on the following fields of study:
His main research concerns Internal medicine, Inflammatory bowel disease, Crohn's disease, Ulcerative colitis and Gastroenterology.
His Vedolizumab, Clinical trial, Adverse effect and Ustekinumab study in the realm of Internal medicine interacts with subjects such as In patient.
The various areas that he examines in his Inflammatory bowel disease study include Epidemiology, Immunology, Coronavirus disease 2019 and Intensive care medicine.
His Crohn's disease research integrates issues from Odds ratio, Infliximab, Calprotectin and C-reactive protein.
His Ulcerative colitis study combines topics from a wide range of disciplines, such as Adalimumab, Tofacitinib, Colitis and Confidence interval.
He interconnects Post-hoc analysis, Placebo and Hazard ratio in the investigation of issues within Gastroenterology.
Between 2017 and 2021, his most popular works were:
- Corticosteroids, But Not TNF Antagonists, Are Associated With Adverse COVID-19 Outcomes in Patients With Inflammatory Bowel Diseases: Results From an International Registry. (211 citations)
- Adherent-invasive Escherichia coli in inflammatory bowel disease (138 citations)
- Vedolizumab versus Adalimumab for Moderate-to-Severe Ulcerative Colitis (132 citations)
In his most recent research, the most cited papers focused on:
- Internal medicine
- Disease
- Cancer
Jean-Frederic Colombel mainly focuses on Internal medicine, Inflammatory bowel disease, Ulcerative colitis, Crohn's disease and Gastroenterology.
His work in Internal medicine covers topics such as Placebo which are related to areas like Randomized controlled trial.
His research integrates issues of Psoriatic arthritis, Epidemiology, Incidence and Immunology in his study of Inflammatory bowel disease.
Jean-Frederic Colombel has researched Ulcerative colitis in several fields, including Clinical trial, Colitis, Retrospective cohort study, Intensive care medicine and Hazard ratio.
His Crohn's disease research also works with subjects such as
- C-reactive protein that connect with fields like Clinical endpoint,
- Colonoscopy which is related to area like Endoscopy.
He combines subjects such as Infliximab, Dysplasia, Meta-analysis, Primary sclerosing cholangitis and Pouchitis with his study of Gastroenterology.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
